Singapur - İngilizce - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - ezetimibe - tablet - ezetimibe 10 mg

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - simvastatin 10mg;  ;  ;  ;   - film coated tablet - 10 mg - active: simvastatin 10mg         excipient: butylated hydroxyanisole hyprolose hypromellose lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc   purified water titanium dioxide - patients at high risk of coronary heart disease (chd) or with existing chd. in patients at high risk of chd (with or without hyperlipidaemia but with a total cholesterol of >3.5 mmol/l), i.e. patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd, simvastatin is indicated to: · reduce the risk of total mortality by reducing chd deaths. · reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, chd death, stroke, or revascularisation procedures. · reduce the risk of stroke. · reduce the need for coronary revascularisation procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty). · reduce the need for peripheral and other non-coronary revascularisation procedures. · reduce the risk of hospitalisation for angina pectoris. in patients with diabetes, simvastatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularisation procedures, lower limb amputations, or leg ulcers. in hypercholesterolaemic patients with coronary heart disease, simvastatin slows the progress of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - simvastatin - oral tablet - 10mg

Singapur - İngilizce - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - ezetimibe; simvastatin - tablet - ezetimibe 10mg; simvastatin 20 mg

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - atorvastatin - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; atorvastatin

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - simvastatin - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; simvastatin

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

teva b.v. - rosuvastatin - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; rosuvastatin - hmg-coa reductase inhibitors - treatment of hypercholesterolaemia adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate. prevention of cardiovascular events prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular even

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

teva b.v. - rosuvastatin - film-coated tablet - 5 milligram(s) - hmg coa reductase inhibitors; rosuvastatin

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

teva b.v. - rosuvastatin - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; rosuvastatin

ABD - İngilizce - NLM (National Library of Medicine)

sandoz inc - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24) - ezetimibe 10 mg - ezetimibe is indicated: when ezetimibe is used in combination with a statin, fenofibrate, or other ldl-c lowering therapies, refer to the prescribing information of these products for information on the safe and effective use. ezetimibe is contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ezetimibe. hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported [see adverse reactions (6.2)] . when used in combination with a statin, fenofibrate, or other ldl-c lowering therapy, ezetimibe is contraindicated in patients for whom a statin, fenofibrate, or other ldl-c lowering therapy are contraindicated. refer to the prescribing information of these products for a list of their contraindications [see warnings and precautions (5.1)] . risk summary there are insufficient data on ezetimibe use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in anim